Pfizer scraps daily weight loss pill after liver injury in one patient
1. Pfizer halts development of its weight loss drug, danuglipron, due to liver injury concerns. 2. This drug's discontinuation reflects ongoing challenges in the GLP-1 competitive market. 3. The oral GLP-1 sector is projected to be worth $50 billion by 2030. 4. Pfizer remains committed to obesity treatments with other drugs still in development. 5. Analysts predict GLP-1 industry could surpass $150 billion, increasing competitive pressure.